{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:16:18Z","timestamp":1785521778612,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40744-026-00852-3","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:25:27Z","timestamp":1778927127000},"page":"1055-1074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106\u00a0Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02760368","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02760407","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02760433","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03120949","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy M.","family":"Fleischmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Lisitsyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Nasonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Samsonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Grishin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Egorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiya","family":"Kuzkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"852_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/11531980-000000000-00000","volume":"70","author":"V Strand","year":"2010","unstructured":"Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010;70:121\u201345. https:\/\/doi.org\/10.2165\/11531980-000000000-00000.","journal-title":"Drugs"},{"key":"852_CR2","first-page":"880","volume":"30","author":"A Carr","year":"2003","unstructured":"Carr A, Hewlett S, Hughes R, et al. Rheumatology outcomes: the patient\u2019s perspective. J Rheumatol. 2003;30:880\u20133.","journal-title":"J Rheumatol"},{"key":"852_CR3","doi-asserted-by":"publisher","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA,  et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356. (Erratum in: Ann Rheum Dis. 2023 Mar;82(3):e76. 10.1136\/ard-2022-223356corr1.","DOI":"10.1136\/ard-2022-223356"},{"issue":"7","key":"852_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339. https:\/\/doi.org\/10.1002\/acr.24596.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"852_CR5","first-page":"2250","volume":"32","author":"JR Kirwan","year":"2005","unstructured":"Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis\u2013progress at OMERACT 7. J Rheumatol. 2005;32:2250\u20136.","journal-title":"J Rheumatol"},{"key":"852_CR6","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3899\/jrheum.110388","volume":"38","author":"JR Kirwan","year":"2011","unstructured":"Kirwan JR, Tugwell PS. Overview of the patient perspective at OMERACT 10\u2014conceptualizing methods for developing patient-reported outcomes. J Rheumatol. 2011;38:1699\u2013701. https:\/\/doi.org\/10.3899\/jrheum.110388.","journal-title":"J Rheumatol"},{"issue":"3","key":"852_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/art.1790050303","volume":"5","author":"DR Ramey","year":"1992","unstructured":"Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res. 1992;5(3):119\u201329. https:\/\/doi.org\/10.1002\/art.1790050303.","journal-title":"Arthritis Care Res"},{"key":"852_CR8","volume-title":"User\u2019s manual for the SF-36v2\u2122 health survey","author":"JE Ware Jr","year":"2007","unstructured":"Ware JE Jr, Kosinski M, Bjorner JB, et al. User\u2019s manual for the SF-36v2\u2122 health survey. 2nd edn. Lincoln: QualityMetric Incorporated; 2007.","edition":"2nd edn"},{"issue":"4","key":"852_CR9","first-page":"234","volume":"14","author":"V Strand","year":"2008","unstructured":"Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2008;14(4):234\u201354.","journal-title":"Am J Manag Care"},{"issue":"5","key":"852_CR10","first-page":"1174","volume":"34","author":"JR Kirwan","year":"2007","unstructured":"Kirwan JR, Minnock P, Adebajo A, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol. 2007;34(5):1174\u20137.","journal-title":"J Rheumatol"},{"key":"852_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/annrheumdis-2021-219876","volume":"81","author":"E Nasonov","year":"2022","unstructured":"Nasonov E, Fatenejad S, Feist E, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81:469\u201379. https:\/\/doi.org\/10.1136\/annrheumdis-2021-219876.","journal-title":"Ann Rheum Dis"},{"key":"852_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1056\/NEJMoa2201302","volume":"387","author":"JS Smolen","year":"2022","unstructured":"Smolen JS, Feist E, Fatenejad S, et al. Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2022;387:715\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2201302.","journal-title":"N Engl J Med"},{"issue":"12","key":"852_CR13","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1136\/ard-2022-222630","volume":"81","author":"E Feist","year":"2022","unstructured":"Feist E, Fatenejad S, Grishin S, et al. Olokizumab, a monoclonal antibody against Interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81(12):1661\u20138. https:\/\/doi.org\/10.1136\/ard-2022-222630.","journal-title":"Ann Rheum Dis"},{"key":"852_CR14","doi-asserted-by":"publisher","unstructured":"Feist E, Fleischmann RM, Fatenejad S, et al. Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. Ann Rheum Dis. 2024;83(11):1454\u201364. https:\/\/doi.org\/10.1136\/ard-2023-225473. (Erratum in: Ann Rheum Dis. 2025 Feb;84(2):373. 10.1136\/ard-2023-225473corr1).","DOI":"10.1136\/ard-2023-225473"},{"key":"852_CR15","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, et al. Validation of the functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811\u20139.","journal-title":"J Rheumatol"},{"key":"852_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/ar2702","volume":"11","author":"JT Osterhaus","year":"2009","unstructured":"Osterhaus JT, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Arthritis Res Ther. 2009;11:R73. https:\/\/doi.org\/10.1186\/ar2702.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"852_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/rheumatology\/33.7.655","volume":"33","author":"NP Hurst","year":"1994","unstructured":"Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H. Validity of EuroQol\u2014a generic health status instrument-in patients with rheumatoid arthritis. Br J Rheumatol. 1994;33(7):655\u201362. https:\/\/doi.org\/10.1093\/rheumatology\/33.7.655.","journal-title":"Br J Rheumatol"},{"issue":"3","key":"852_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40744-020-00219-2","volume":"7","author":"EG Favalli","year":"2020","unstructured":"Favalli EG. Understanding the role of Interleukin-6 (IL-6) in the joint and beyond: a comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis. Rheumatol Ther. 2020;7(3):473\u2013516. https:\/\/doi.org\/10.1007\/s40744-020-00219-2.","journal-title":"Rheumatol Ther"},{"key":"852_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000602.23","volume":"4","author":"V Strand","year":"2018","unstructured":"Strand V, Michalska M, Birchwood C, et al. Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of life outcomes in patients with rheumatoid arthritis. RMD Open. 2018;4:e000602. https:\/\/doi.org\/10.1136\/rmdopen-2017-000602.23.","journal-title":"RMD Open"},{"issue":"10","key":"852_CR20","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1093\/rheumatology\/kes131","volume":"51","author":"V Strand","year":"2012","unstructured":"Strand V, Burmester GR, Ogale S, Devenport J, John A, Emery P. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford). 2012;51(10):1860\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/kes131.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"852_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1096-9","volume":"18","author":"V Strand","year":"2016","unstructured":"Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18(1):198. https:\/\/doi.org\/10.1186\/s13075-016-1096-9.","journal-title":"Arthritis Res Ther"},{"key":"852_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000416","volume":"3","author":"V Strand","year":"2017","unstructured":"Strand V, Reaney M, Chen C-I, et al. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response\/ intolerance to tumour necrosis factor inhibitors. RMD Open. 2017;3:e000416. https:\/\/doi.org\/10.1136\/rmdopen-2016-000416.","journal-title":"RMD Open"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00852-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:06:58Z","timestamp":1785517618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00852-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00852-3","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Roy M Fleischmann is an Editor-in-Chief of\n                      Rheumatology and Therapy\n                      . Roy M Fleischmann was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Roy M Fleischmann reports consulting fees for AbbVie, Almirall, Anaptys, Artiva Biotherapeutics, Atomwise, Biohaven Pharmaceuticals, BMS. Cyoxone, Deep Cure, Dren Bio, ECOR, Eisai, Galvani, Gates Bio, Genentech, Gilead, GSK, Halia, Immunovant, ImmuneMed, InventisBio, Istesso, Janssen, Janux, Eli Lilly, MSD, Monte Rosa, Overland, Novartis, Pfizer, Roche, RPharm, Synact, TPG, UCB, Vyne and Xencor; Vibeke Strand reports consulting fees for Abbvie, Amgen, Andera, Arthrosi, Artiva, Astra Zeneca, Autolus, Bayer, BMS, Boehringer Ingelheim, Catalys, Contura, Cullinan, Fate Rx, Fortress Biotech, Gate Biosciences, GSK, Inmedix, Kiniksa, Lipum, Longitude Capital, MED Institute, Novartis, Pacira, RAPT, Royalty Pharma, Samsung Bioepis, Sanofi, Scipher, Setpoint, Sobi, Soleil, Spherix, Synact, Takeda, Wield and Zoe, and participation for AstraZeneca DSMB. Eugen Feist reports grants or research support from Eli Lilly, Novartis, Pfizer, Alfasigma; serving as a consultant for AbbVie, Eli Lilly, Galapagos, Medac, Novartis, Sanofi, Sobi, R-Pharm and Alfasigma. Tatiana Lisitsyna reports consulting fees for R-Pharm. Jeffrey A Sparks reports grants\/research support from National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Heart, Lung, and Blood Institute, Rheumatology Research Foundation, Arthritis Foundation, R Bruce and Joan M Mickey Research Scholar Fund, Gordon and Llura Gund Foundation, Bristol Myers Squibb, Boehringer Ingelheim, Johnson & Johnson, and Sonoma Biotherapeutics; and serving as a consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius Kabi, Gilead, Inova Diagnostics, Johnson & Johnson, Merck, MustangBio, Novartis, Optum, Pfizer, ReCor, Sana, Sobi and UCB. Evgeny Nasonov has nothing to disclose. Mikhail Samsonov, Sergey Grishin, Alina Egorova and Sofiya Kuzkina are employees of R-Pharm. Josef S. Smolen reports grants\/research support from AbbVie, BMS, Celgene, Chugai, Eli Lilly, Gilead, Janssen, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi and UCB; and serving as a consultant for AbbVie, BMS, Celgene, Chugai, Eli Lilly, Gilead, Janssen, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi and UCB.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trials were conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines and approved by the Institutional Review Board or Ethics Committee at each center. \u201cR-Pharm\u201d, as the study sponsor, obtained permission to use all the scales\/questionnaires within the studies. All patients provided written informed consent. The list of sites are provided with the primary articles as electronic supplementary material files.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}